Johnson & Johnson (NYSE:JNJ) Shares Sold by Flagship Harbor Advisors LLC

Flagship Harbor Advisors LLC trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 6.3% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 31,977 shares of the company’s stock after selling 2,162 shares during the period. Flagship Harbor Advisors LLC’s holdings in Johnson & Johnson were worth $5,293,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in JNJ. Gradient Investments LLC raised its stake in shares of Johnson & Johnson by 10.4% in the second quarter. Gradient Investments LLC now owns 201,459 shares of the company’s stock valued at $33,346,000 after acquiring an additional 19,046 shares in the last quarter. Beech Hill Advisors Inc. increased its holdings in Johnson & Johnson by 0.3% in the second quarter. Beech Hill Advisors Inc. now owns 23,595 shares of the company’s stock valued at $3,906,000 after buying an additional 63 shares during the last quarter. Castle Rock Wealth Management LLC increased its holdings in Johnson & Johnson by 1.1% in the second quarter. Castle Rock Wealth Management LLC now owns 11,526 shares of the company’s stock valued at $1,877,000 after buying an additional 124 shares during the last quarter. Good Life Advisors LLC grew its holdings in shares of Johnson & Johnson by 11.0% during the second quarter. Good Life Advisors LLC now owns 23,300 shares of the company’s stock worth $3,857,000 after purchasing an additional 2,310 shares during the last quarter. Finally, Sanders Morris Harris LLC grew its holdings in shares of Johnson & Johnson by 82.1% during the second quarter. Sanders Morris Harris LLC now owns 8,320 shares of the company’s stock worth $1,368,000 after purchasing an additional 3,750 shares during the last quarter. 68.40% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Johnson & Johnson

In other news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total value of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at approximately $17,491,182.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Hait sold 14,698 shares of the business’s stock in a transaction on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several research reports. HSBC assumed coverage on Johnson & Johnson in a report on Wednesday, September 6th. They set a “hold” rating and a $175.00 price objective on the stock. Atlantic Securities raised their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $175.00 to $180.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Raymond James lowered their price target on Johnson & Johnson from $184.00 to $179.00 and set an “outperform” rating on the stock in a report on Tuesday, September 5th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Monday. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $170.65.

Johnson & Johnson Price Performance

JNJ stock opened at $162.41 on Tuesday. The firm has a 50 day moving average of $166.21 and a 200-day moving average of $161.83. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The company has a market cap of $422.10 billion, a price-to-earnings ratio of 32.88, a PEG ratio of 3.26 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company had revenue of $25.53 billion during the quarter, compared to the consensus estimate of $24.63 billion. During the same period last year, the firm earned $2.59 EPS. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.03 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. Johnson & Johnson’s payout ratio is 96.36%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.